Publications by authors named "Nongkanok Khanarat"

Background: Limited data exists regarding population immunity against diphtheria, tetanus, and pertussis in Thailand during the post-COVID-19 pandemic period. This study aimed to evaluate the age-specific seroprevalence of anti-diphtheria toxoid (anti-DT) IgG, anti-tetanus toxoid (anti-TT) IgG, and anti-pertussis toxin (anti-PT) IgG in individuals across diverse age groups in Chonburi province, Thailand following the COVID-19 pandemic.

Methods: Between October 2022 and January 2023, a total of 657 participants from Chonburi Province, Thailand, were included in this study.

View Article and Find Full Text PDF

Seroprevalence studies on SARS-CoV-2 are essential for estimating actual prevalence rates of infection and vaccination in communities. This study evaluated infection rates based on total anti-nucleocapsid immunoglobulin (N) and/or infection history. We determined the seroprevalence of anti-receptor binding domain (RBD) antibodies across age groups.

View Article and Find Full Text PDF

The Coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), continues to surge despite the widespread use of vaccination. In Thailand, more than 77% and 39% of the population received two doses and three doses of COVID-19 vaccines as of December 2022, respectively. In addition, during the Omicron predominant period in 2022, more than 70% of Thai individuals have been infected.

View Article and Find Full Text PDF
Article Synopsis
  • A study at King Chulalongkorn Memorial Hospital in Thailand compared the safety and immune response of two doses of an mRNA COVID-19 vaccine with one or two doses of an inactivated vaccine followed by the mRNA vaccine in children aged 5 to 11 from March to June 2022.
  • Among 166 healthy children enrolled, mild to moderate side effects occurred within a week after vaccination, indicating good tolerability for both regimens.
  • The results showed that while all groups had similar antibody responses, those receiving two doses of mRNA or two doses of BBIBP-CorV followed by mRNA had stronger immunity against Omicron variants compared to those receiving CoronaVac followed by mRNA, suggesting that a
View Article and Find Full Text PDF

The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines. This prospective cohort study was conducted between June and October 2022. The self-recorded reactogenicity was evaluated on the subsequent 7 days after a fourth dose.

View Article and Find Full Text PDF

Coxsackievirus (CV)-A6 infections cause hand, foot, and mouth disease (HFMD) in children and adults. Despite the serious public health threat presented by CV-A6 infections, our understanding of the mechanisms by which new CV-A6 strains emerge remains limited. This study investigated the molecular epidemiological trends, evolutionary dynamics, and recombination characteristics of CV-A6-associated HFMD in Thailand between 2019 and 2022.

View Article and Find Full Text PDF

Objectives: To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax) given as a third (booster) dose to individuals primed with different primary vaccine regimens.

Methods: A third dose was administered to individuals with an interval range of 3-10 months after the second dose. The four groups were classified according to their primary vaccine regimens, including two-dose BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222.

View Article and Find Full Text PDF